Teong Lee-Fang, Khor Ban-Hock, Radion Purba Kristo, Gafor Abdul Halim Abdul, Goh Bak-Leong, Bee Boon-Cheak, Yahya Rosnawati, Bavanandan Sunita, Ng Hi-Ming, Sahathevan Sharmela, Narayanan Sreelakshmi Sankara, Daud Zulfitri Azuan Mat, Khosla Pramod, Karupaiah Tilakavati
School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya 47500, Malaysia.
Department of Dietetics and Food Service, Selayang Hospital, Batu Caves 68100, Malaysia.
Healthcare (Basel). 2022 Mar 14;10(3):535. doi: 10.3390/healthcare10030535.
Hyperphosphatemia afflicts end-stage chronic kidney disease (CKD) patients, contributing to comorbidities and mortality. Management strategies are dialysis, phosphate binder, and limiting dietary phosphate intake, but treatment barriers are poor patient compliance and low health literacy arising from low self-efficacy and lack of educational resources. This study describes developing and validating a phosphate mobile application (PMA). The PMA development based on the seven-stage prioritized titrating dietary phosphate intake with phosphate binder dose supported by educational videography. Experts ( = 13) first evaluated the PMA for knowledge-based accuracy, mobile heuristics, and clinical value. Adult HD patients validated the improved PMA using the seven-point mHealth App Usability Questionnaire (MAUQ). Patient feedback ( = 139) indicated agreement for (69.2%), (69.0%), and (70.1%), while 72.7% said they would this PMA. The for 25 PMA features ranged from 92.1% () up to 100.0% (); and the utilization rate of each feature varied from 21.6% ( and ) to 91.4% ( on and ). The Conclusions: PMA was acceptable to adult Malaysian HD patients as part of clinical phosphate management in low-resource settings.
高磷血症困扰着终末期慢性肾脏病(CKD)患者,会导致多种并发症和死亡。管理策略包括透析、使用磷结合剂以及限制饮食中磷的摄入量,但治疗障碍包括患者依从性差以及由于自我效能低和缺乏教育资源导致的健康素养低下。本研究描述了一种磷移动应用程序(PMA)的开发和验证过程。PMA的开发基于七阶段优先滴定饮食中磷的摄入量,并结合教育视频来确定磷结合剂的剂量。13名专家首先对PMA的知识准确性、移动启发式设计和临床价值进行了评估。成年血液透析患者使用七点移动健康应用程序可用性问卷(MAUQ)对改进后的PMA进行了验证。139名患者的反馈表明,对[具体内容1]的认同率为69.2%,对[具体内容2]的认同率为69.0%,对[具体内容3]的认同率为70.1%,而72.7%的患者表示他们会使用这款PMA。25个PMA功能的认同率从92.1%([具体功能1])到100.0%([具体功能2])不等;每个功能的使用率从21.6%([具体功能3]和[具体功能4])到91.4%([具体功能5]在[具体情况1]和[具体情况2]下)不等。结论:在资源匮乏的环境中,作为临床磷管理的一部分,PMA为成年马来西亚血液透析患者所接受。